---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-054942"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:49:35.562975+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cryoport Q1 revenue $47.8M (+16% YoY); raises FY2026 guidance to $192-196M

## Summary
- Q1 revenue $47.8M (+16% YoY); commercial CGT revenue $9.1M (+26%).
- Life Sciences Services revenue $26.9M (+18%); BioStorage/BioServices up 21%.
- Supported 766 global clinical trials (91 Phase 3) and 21 commercial CGTs as of March 31.
- FY2026 revenue guidance raised to $192M-$196M versus prior outlook.
- Four BLA/MAA filings in Q1; Rocket Pharma FDA approval for KRESLADI gene therapy.

## SEC filing metadata
- accession: 0001104659-26-054942
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465926054942/0001104659-26-054942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465926054942/tm2613494d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-054942
- JSON: https://secwatch.observer/filing/0001104659-26-054942.json
- Plain text: https://secwatch.observer/filing/0001104659-26-054942.txt

## Key facts
- Earnings Releases
  Cryoport, Inc. reported first quarter (Q1) of 2026 results: revenue $47.8 million. Guidance raised.
  - Period: first quarter (Q1) of 2026
  - Revenue: $47.8 million
  - Guidance: raised
  - Result: reported results
  source text: 99.1) --- EX-99.1 2 tm2613494d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports First Quarter 2026 Financial Results ● First quarter revenue grew 16% year-over-year to $47.8 million ● Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programs ● Life Sciences Services
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124524/000110465926054942/0001104659-26-054942-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.